World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 92 11180 10507 5750 5318 914 36577

Maurie Markman publications per year

The chart shows the history of publications by Maurie Markman between 1980 and 2023, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Maurie Markman published across 44 years, from 1980 to 2023, averaging 21.1 papers a year. Output peaked at 58 publications in 2007. 16 of the 927 publications appeared in the last two years.

No. of publications
10 20 30 40 50
Bar chart. Horizontal axis: year, 1980 to 2023. Vertical axis: number of publications, 0 to 58. Peak 58 publications in 2007. 1980: 1 publication 1981: 4 publications 1982: 6 publications 1983: 3 publications 1984: 13 publications 1985: 11 publications 1986: 5 publications 1987: 8 publications 1988: 6 publications 1989: 10 publications 1990: 8 publications 1991: 19 publications 1992: 24 publications 1993: 30 publications 1994: 25 publications 1995: 17 publications 1996: 25 publications 1997: 25 publications 1998: 23 publications 1999: 19 publications 2000: 23 publications 2001: 21 publications 2002: 22 publications 2003: 45 publications 2004: 39 publications 2005: 30 publications 2006: 56 publications 2007: 58 publications 2008: 45 publications 2009: 43 publications 2010: 44 publications 2011: 29 publications 2012: 22 publications 2013: 23 publications 2014: 30 publications 2015: 16 publications 2016: 23 publications 2017: 9 publications 2018: 22 publications 2019: 22 publications 2020: 6 publications 2021: 1 publication 2022: 10 publications 2023: 6 publications
1980 2023

927 publications in total across all disciplines

View publications per year as a table
Maurie Markman: publications per year, 1980 to 2023
Year Publications
1980 1
1981 4
1982 6
1983 3
1984 13
1985 11
1986 5
1987 8
1988 6
1989 10
1990 8
1991 19
1992 24
1993 30
1994 25
1995 17
1996 25
1997 25
1998 23
1999 19
2000 23
2001 21
2002 22
2003 45
2004 39
2005 30
2006 56
2007 58
2008 45
2009 43
2010 44
2011 29
2012 22
2013 23
2014 30
2015 16
2016 23
2017 9
2018 22
2019 22
2020 6
2021 1
2022 10
2023 6
Total 927
Download as CSV

Maurie Markman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Maurie Markman sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 901–920 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 914 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145 914
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Maurie Markman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Maurie Markman sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 92–93 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 92 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839 92
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Maurie Markman is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medical and molecular biology fields, with substantial contributions to cancer research and reproductive medicine.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Markman's work covers several subfields, notably:

  • Cancer Research
  • Reproductive Medicine
  • Oncology
  • Pulmonary and Respiratory Medicine
  • Epidemiology

The main research topics they address are:

  • Cancer Genomics and Diagnostics
  • Ovarian cancer diagnosis and treatment
  • Renal cell carcinoma treatment
  • Pancreatic and Hepatic Oncology Research
  • Intraperitoneal and Appendiceal Malignancies
  • Endometrial and Cervical Cancer Treatments
  • Molecular Biology Techniques and Applications

Maurie Markman has contributed to numerous scientific publications across various venues. Frequent publication outlets include:

  • Journal of Clinical Oncology
  • Gynecologic Oncology Reports
  • Gynecologic Oncology
  • Future Virology
  • Cancer Research

Recent papers by Markman highlight topics in ovarian and pancreatic cancers and include:

  • What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer, 2022, Gynecologic Oncology
  • Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery, 2020, Gynecologic Oncology Reports
  • Mutational landscape of pancreatic adenocarcinoma identified by prospective clinical sequencing in a nationwide cancer network, 2022, Journal of Clinical Oncology
  • Racial differences in the mutational landscape of serous endometrial cancer, 2022, Journal of Clinical Oncology
  • 36 Mutational landscape of low-grade serous carcinoma of the ovary, 2022, Gynecologic Oncology Reports

Their collaborative network includes frequent co-authors such as:

  • Vicki Doctor
  • Amber Moran
  • Julian C. Schink
  • Julia A. Elvin
  • Natalie Godbee

Best Publications

  • Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group

    Maurie Markman;Brian N. Bundy;David S. Alberts;Jeffrey M. Fowler

  • Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

    M Markman;R Rothman;T Hakes;B Reichman

  • Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

    William E. Winter;G. Larry Maxwell;Chunqiao Tian;Jay W. Carlson

  • Lysophosphatidic Acid as a Potential Biomarker for Ovarian and Other Gynecologic Cancers

    Yan Xu;Zhongzhou Shen;Donald W. Wiper;Minzhi Wu

  • Ovarian Cancer: Screening, Treatment, and Follow-up

    Vicki Seltzer;Bruce H. Drukker;Brenda W. Gillespie;Lynn M. Gossfeld

  • Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

    Maurie Markman;P.Y. Liu;Sharon Wilczynski;Bradley Monk

  • Clinical Features of Hypersensitivity Reactions to Carboplatin

    Maurie Markman;Alexander Kennedy;Kenneth Webster;Paul Elson

  • Paclitaxel in cancer therapy.

    Tarek M Mekhail;Maurie Markman

  • Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

    Bryan T.J. Hennessy;Kirsten M. Timms;Mark S. Carey;Alexander Gutin

  • Second-line treatment of ovarian cancer.

    Maurie Markman;Michael A. Bookman

  • Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.

    M Markman;E Rowinsky;T Hakes;B Reichman

  • Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.

    Howard D. Homesley;Virginia Filiaci;Maurie Markman;Pincas Bitterman

  • Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

    Maurie Markman;John Blessing;Stephen C. Rubin;Joseph Connor

  • Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer

    Maurie Markman;James Hall;Daniel Spitz;Sheldon Weiner

  • Long-Term Survival of Advanced Refractory Ovarian Carcinoma Patients with Small-Volume Disease Treated with Intraperitoneal Chemotherapy

    Stephen B. Howell;Soloman Zimm;Maurie Markman;Ian S. Abramson

  • Intraperitoneal antineoplastic drug delivery: rationale and results

    Maurie Markman

  • RESPONSES TO SALVAGE CHEMOTHERAPY IN OVARIAN CANCER: A CRITICAL NEED FOR PRECISE DEFINITIONS OF THE TREATED POPULATION

    M Markman;W Hoskins

  • Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design

    Maurie Markman;Jonathan Markman;Kenneth Webster;Kristine M. Zanotti

  • Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology

    Eric Winer;Julie Gralow;Lisa Diller;Beth Karlan

  • Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.

    M Markman;B Reichman;T Hakes;W Jones

Frequent Co-Authors

William J. Hoskins
William J. Hoskins Memorial Sloan Kettering Cancer Center
Stephen C. Rubin
Stephen C. Rubin University of Pennsylvania
Stephen B. Howell
Stephen B. Howell University of California, San Diego
Richard R. Barakat
Richard R. Barakat Northwell Health
David S. Alberts
David S. Alberts University of Arizona
Mark G. Kris
Mark G. Kris Memorial Sloan Kettering Cancer Center
Lynn M. Schuchter
Lynn M. Schuchter University of Pennsylvania
Yoshihiko Maehara
Yoshihiko Maehara Kyushu University
Raymond Sawaya
Raymond Sawaya The University of Texas MD Anderson Cancer Center
Patricia A. Ganz
Patricia A. Ganz University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA involves various educational routes, including flexible online options for those seeking advanced nursing or entry-level roles. Accelerated online programs are gaining popularity, allowing students to earn credentials faster and join the healthcare workforce sooner.

For nurses aiming to reach the highest clinical degrees, several universities offer the shortest post master's DNP program, letting experienced nurses complete their Doctor of Nursing Practice in less time. Additionally, various DNP online programs are designed for flexibility and accessibility, ideal for working professionals balancing studies and career.

If you’re interested in psychiatric nursing, some schools provide the shortest post master's PMHNP online programs, preparing nurses for specialized roles in mental health in record time.

Those starting out can consider entry-level options, such as a LPN program online, which enables rapid entry into the nursing field.

With these diverse choices, prospective healthcare professionals can find pathways that match their personal goals, timelines, and learning preferences.

Best Scientists Citing Maurie Markman

Trending Scientists

Recently Published Articles